4-Apr-2025
No headlines found.
Immunocore to present at upcoming investor conferences
Globe Newswire (Wed, 2-Apr 8:00 AM ET)
Globe Newswire (Mon, 10-Mar 3:00 PM ET)
Globe Newswire (Wed, 26-Feb 7:00 AM ET)
Globe Newswire (Wed, 19-Feb 7:00 AM ET)
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Fri, 10-Jan 7:00 AM ET)
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 6-Jan 7:00 AM ET)
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Immunocore Holdings PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol IMCR.
As of April 4, 2025, IMCR stock price declined to $27.26 with 284,648 million shares trading.
IMCR has a beta of 0.76, meaning it tends to be less sensitive to market movements. IMCR has a correlation of 0.06 to the broad based SPY ETF.
IMCR has a market cap of $1.36 billion. This is considered a Small Cap stock.
Last quarter Immunocore Holdings PLC - American Depositary Shares reported $84 million in Revenue and -$.47 earnings per share. This beat revenue expectation by $502,000 and missed earnings estimates by -$.23.
In the last 3 years, IMCR traded as high as $76.98 and as low as $25.01.
The top ETF exchange traded funds that IMCR belongs to (by Net Assets): IBB, SPDW, SBIO, GWX, ONEQ.
IMCR has underperformed the market in the last year with a price return of -57.2% while the SPY ETF lost -1.3%. However, in the short term, IMCR had mixed performance relative to the market. It has outperformed in the last 3 months, returning -8.7% vs -14.4% return in SPY. But in the last 2 weeks, IMCR shares have been beat by the market, returning -10.4% compared to an SPY return of -10.1%.
IMCR support price is $27.93 and resistance is $30.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMCR shares will trade within this expected range on the day.